Emergency Medicine · Medical Literature
Peak Expiratory flow Rate for Emergency Department Management of Acute Asthma Exacerbation: A Randomized Controlled Trial Pilot Study.
Abstract
Peak expiratory flow rate (PEFR) is used to assess asthma severity, and guidelines recommend serial PEFR measurements to guide management. However, the evidence behind this practice is limited. To compare outcomes between PEFR-guided and non-PEFR-guided emergency department (ED) care for acute asthma exacerbations. This randomized, unblinded, two-arm study compared PEFR-guided therapy with symptom-guided therapy in ED patients aged 16 to 55 years presenting with acute asthma without chronic obstructive pulmonary disease (COPD). Patients were enrolled within 15 min of their first nebulizer treatment. PEFR was measured at baseline and every 30 min until symptom resolution, discharge, or admission. Clinicians in the PEFR-guided group received PEFR values with guideline-based recommendations, while clinicians in the non-PEFR-guided group were blinded to PEFR values. The primary outcome was the proportion of patients with none or mild asthma symptoms by 150 min after enrollment. The secondary outcome was hospitalization. A total of 210 patients were enrolled (101 PEFR-guided; 109 non-PEFR-guided). Symptom control by 150 min occurred in 73 (72%) vs. 78 (72%) patients (95% CI, -11% to 13%). Hospitalization was similar: 17 (17%) in the PEFR group vs. 13 (12%) in the non-PEFR group (95% CI, -5% to 14%). Subgroup hospitalization results by percent-predicted PEFR were comparable. There was no difference in nebulized medication use. In this randomized trial, PEFR-guided care did not improve symptom control, reduce resource utilization, or affect disposition compared with symptom-guided care. These findings suggest limited benefit of PEFR use in ED asthma management. Larger, multicenter studies are needed before informing practice changes.
Clinical relevance
In adult ED patients aged 16–55 years presenting with acute asthma exacerbation (without COPD), does serial PEFR-guided management improve symptom control at 150 minutes or reduce hospitalization rates compared with symptom-guided care alone? __SNAPSHOT__ {"studyDesign":"Randomized controlled trial (pilot study); unblinded, two-arm parallel-group design","setting":"Emergency department; country and institution type not reported in abstract","sampleSize":"n=210 (PEFR-guided: n=101; non-PEFR-guided: n=109)","population":"ED patients aged 16–55 years with acute asthma exacerbation, explicitly excluding patients with concurrent COPD; enrolled within 15 minutes of first nebulizer treatment","intervention":"PEFR-guided therapy: serial PEFR measurements at baseline and every 30 minutes until symptom resolution, discharge, or admission; clinicians received PEFR values paired with guideline-based management recommendations (NAEPP percent-predicted thresholds)","comparator":"Symptom-guided therapy: clinicians were blinded to PEFR values; management based on symptoms, physical examination, vital signs, and clinical judgment","primaryOutcome":"Proportion of patients achieving none or mild asthma symptoms by 150 minutes after enrollment","followUp":"150 minutes for primary endpoint; hospitalization assessed as secondary outcome (duration of inpatient follow-up not reported)","fundingSource":"Not reported"}
Key findings
Primary outcome: Symptom control by 150 minutes was achieved in 73/101 (72%) of PEFR-guided patients versus 78/109 (72%) of non-PEFR-guided patients — an absolute risk difference of 0% (95% CI, −11% to +13%; p-value not reported in abstract). The confidence interval is consistent with no clinically meaningful benefit or harm from PEFR-guided care. NNT is not calculable given the identical proportions observed. Time-to-symptom-control analysis (Kaplan–Meier) yielded a hazard ratio of 1.13 (95% CI, 0.82–1.56; log-rank p=0.481), further confirming no significant difference in the trajectory of symptom resolution between groups. Secondary outcome: Hospitalization rates were numerically higher in the PEFR-guided group — 17/101 (17%) versus 13/109 (12%) in the non-PEFR group — with an absolute difference of +5% (95% CI, −5% to +14%); this difference was not statistically significant and the CI crosses zero. Subgroup hospitalization analyses stratified by percent-predicted PEFR showed comparable results across groups. Nebulized medication utilization (albuterol and albuterol-ipratropium) did not differ between the two groups at any reassessment point. No safety outcomes or adverse events were specifically reported in the abstract.
Practice implications
This pilot RCT found no detectable benefit of serial PEFR-guided management over symptom-guided care for acute asthma in the ED across symptom control, hospitalization rates, or bronchodilator utilization. The findings are consistent with the observation that, in practice, clinicians receiving PEFR values with guideline recommendations did not meaningfully alter their management or disposition decisions compared with those relying on clinical assessment alone. Importantly, this was an explicitly labeled pilot study — it was likely underpowered to detect modest but clinically meaningful differences, and the 95% CI for the primary outcome (−11% to +13%) is wide enough to neither rule in nor rule out a small but potentially important effect. The study population was restricted to ages 16–55 without COPD, limiting generalizability to older patients, those with mixed obstructive disease, or pediatric populations. Patients with severe or life-threatening exacerbations (who may derive the greatest benefit from objective lung function measurement) may have been underrepresented. Only an abstract was available for review; full methodology, randomization fidelity, allocation concealment, baseline severity distribution, and adherence to PEFR-guided recommendations require evaluation of the complete manuscript before definitive practice conclusions are drawn. Practice change is not warranted on the basis of this single pilot study alone. __LIMITATIONS__ Explicitly a pilot study — almost certainly underpowered to detect small but clinically meaningful differences; the wide confidence interval (−11% to +13%) for the primary outcome reflects this uncertainty.,Unblinded design: clinicians in both groups were aware of study arm assignment, introducing performance bias; patients in the symptom-guided arm may have received covert adjustments based on clinical intuition that incorporates implicit objective assessment.,Clinician adherence to PEFR-based guideline recommendations in the PEFR-guided arm is not reported in the abstract — it is unknown whether management actually diverged between arms in practice, which would critically undermine the internal validity of the trial.,Single-center or limited-center design (institution not specified) limits generalizability.,Age restriction (16–55 years) and COPD exclusion reduce applicability to the full spectrum of ED asthma patients.,Short follow-up window (150 minutes for primary outcome); downstream outcomes such as 72-hour return visits, re-hospitalization, or relapse after discharge were not reported.,Funding source not reported; potential conflicts of interest cannot be assessed.,Symptom control was a patient-reported, subjective primary endpoint — while clinically meaningful, it may be variably interpreted across patients, and no validated asthma symptom score (e.g., Borg scale, modified Borg, Breathlessness scale) is specified in the abstract.,Baseline PEFR severity distribution across arms not described in the abstract; imbalance in exacerbation severity at enrollment could confound results. __BOTTOM_LINE_CATEGORY__ promising_but_preliminary __BOTTOM_LINE__ This pilot RCT found no difference in symptom control at 150 minutes or hospitalization rates between PEFR-guided and symptom-guided ED management of acute asthma, with both groups achieving 72% symptom control and comparable disposition outcomes. However, as an underpowered, unblinded pilot study with wide confidence intervals and limited adherence data, these results are hypothesis-generating rather than practice-changing. Larger, adequately powered, multicenter trials with rigorous protocol adherence monitoring are needed before routine ED PEFR monitoring is abandoned or endorsed on the basis of this evidence.